How Busulfan testing improved the management of Bone Marrow Transplant Patients

Date:  May 26, 2021

Time: 7:30am (IST), 10:00am (CST), 12pm (AEST)

Therapeutic drug monitoring (TDM) of Busulfan is essential for management of Bone Marrow Transplant (BMT) patients, by optimizing dose, supporting compliance, and minimizing toxicity. Busulfan is a chemotherapeutic agent used as a component in a myeloablative preconditioning regimen before hematological stem cell transplantation. A liquid chromatography-tandem mass spectrometry method for rapid and accurate quantification of Busulfan in plasma was developed and validated in the Department of Chemistry at Baptist Hospital of Miami. The TDM and timely plasma concentration reporting of Busulfan would provide an improvement in the quality-of-care for BMT patients. 

Learning Objectives

• Identify our purpose to measure Busulfan in BMT patients’ samples.
• Describe a clinical method to measure Busulfan in plasma by LC-MS/MS.
• Describe the validation results of the method to measure Busulfan in plasma by LC-MS/MS.

Webinars will be available for unlimited on-demand viewing after live event.